… items), the company’s earnings fell 16.7%. Reported earnings were hurt by the costs incurred to acquire Abraxis BioScience , which was completed in October 2010. (Read our full coverage of the earnings report at Q4 Sales Swell at Celgene …
… expectations for the full year . While we had expected to slightly lower our fair value estimate after factoring in the Abraxis ABII acquisition , we have now raised our assumptions for Revlimid sales in 2010 and beyond , countering any impact on our valuation …
… push beyond hematological cancers and into solid tumors, Celgene CELG has announced that it plans to acquire Abraxis BioScience ABII in a deal valued at $2.9 billion, net of cash. Celgene will complete the deal in the fourth quarter of 2010 …
… has been applauded by investors for its recent acquisitions and strong cash position. On the other hand, Abraxis BioScience ABII , which held up well in 2008, has taken a hit so far this year. Overall, the fund has fared well for the year …
… of the mid-cap growth category for the year. Pharmaceutical and biotech holdings like Biogen Idec BIIB and Abraxis BioScience ABII , for example, only lost 16.3% and 4.1%, respectively. Not all picks were so lucky, though; drug manufacturer …
On Friday, Abraxis Bioscience ( ABII ) filed its proxy and one of the things that jumped out at me was the hefty increase in security expenses for Chairman and CEO …
… order to focus on other investment opportunities in the health-care sector. Following the recent spin-off of Abraxis BioScience ABII , APP will focus exclusively on generic injectable drugs. This has been a durable, profitable niche. However …
We're placing Abraxis BioScience 's ABBI fair value estimate under review as we digest a disclosure statement, released Thursday, that provides detailed segment …
We're maintaining our fair value estimate for Abraxis BioScience ABBI following Monday's announced spin-off of APP, the firm's generic injectable drug division. Money-losing Abraxis …
… management does not expect to begin new trials for LEP-ETU until late this year--thanks in part to the success of Abraxis BioScience 's ABBI Abraxane, another Taxol follow-on that has raised the bar for chemotherapeutics in the breast-cancer …